MGRX Company Profile and Key Details

MGRX has shown weak momentum, losing -22.09% over the past week and -74.41% over the past quarter, though year-to-date performance is down -17.35%. Short-term trend indicators are bullishly aligned (SMA20 31.7%, SMA50 -21.31%, SMA200 -66.04%). The stock’s 14-day RSI is 53.22 (neutral), while the ATR of 0.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -91.38% below its high and over 55.84% above its low. Average 10-day trading volume of 49.59 million shares is significantly above the 3-month average of 6.35 million, indicating heightened recent market interest.

Mangoceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$4.42. This means the shares are trading below this model’s fair value.

Mangoceuticals, Inc. has 10.89 million shares outstanding. The public float is 7.81 million shares, elevated short interest at 3.15% of float. This equals 279.20 thousand shares. The short ratio is 1.83 days. Institutional investors hold 3.97% of the float. Insiders own 30.18%. Cohen Jacob D. holds 8.28 million shares, JOHNSTON EUGENE M has 120.00 thousand shares and Hamilton Alex P. has 3.33 thousand shares. Over the past six months, insider transactions show net selling. They sold 143.33 thousand shares across 4 transactions.

Mangoceuticals, Inc. (NASDAQ:MGRX) closed at $0.53 USD, gaining $0.17 (48.83%) from the previous close of $0.36. The stock is currently mid-range between its 52-week high and low $0.34 and $6.15. With a market capitalization of about $6.06 million, Mangoceuticals, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.71). Key stats such as the average daily volume over the past year has been around 634.95 thousand shares, trading with heavier-than-usual volume. Headquartered in Dallas, TX, Mangoceuticals, Inc. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Jacob D. Cohen, the company employs approximately 3 people and listed since March 21, 2023. Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform.

Mangoceuticals, Inc. (NASDAQ:MGRX) shares are down -17.35% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Mangoceuticals, Inc. trading at a premium to the broader market with a P/E of -0.31. Our AI forecast model points to short-term weakness (-50.94% over two weeks), a medium-term fall (-94.34% over three months), and a longer-term loss (-79.25% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Mangoceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -50.94%, with price expected at $0.26 by March 06, 2026, within a range of $0.16 to $0.37 3-Month Outlook: Projected fall of -94.34%, reaching $0.03 by May 21, 2026, with a range of $0.00 to $0.16. 1-Year Outlook: Projected loss of -79.25%, with price at $0.11 by February 19, 2027, within a range of $0.00 to $0.50.

Mangoceuticals, Inc. trades at a P/E ratio of -0.31, slightly below the S&P 500 average, with a price-to-sales ratio of 12.98 and a price-to-book ratio of 0.39 suggesting the stock is closer to book value. The P/FCF stands at -1.03, also above market averages.